Search Results

There are 7862631 results for: content related to: Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

  1. You have free access to this content
    HCV Therapeutics: Approved Agents


    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Version of Record online : 15 OCT 2013, DOI: 10.1002/hep.26880

  2. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations

    The Journal of Clinical Pharmacology

    Volume 55, Issue 5, May 2015, Pages: 517–524, Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie and Etienne Brochot

    Version of Record online : 4 FEB 2015, DOI: 10.1002/jcph.454

  3. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Version of Record online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  4. You have free access to this content
    AASLD Abstracts


    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Version of Record online : 1 OCT 2012, DOI: 10.1002/hep.26040

  5. Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 176–183, Harald Farnik, Tim Zimmermann, Eva Herrmann, Wolf O. Bechstein, Bernd Kronenberger, Peter R. Galle, Sandra Labocha, Nerea Ferreiros, Gerd Geisslinger, Stefan Zeuzem, Christoph Sarrazin and Martin W. Welker

    Version of Record online : 9 APR 2014, DOI: 10.1111/liv.12532

  6. You have full text access to this OnlineOpen article
    Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1043–1049, Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne and Stephen Piscitelli

    Version of Record online : 20 OCT 2014, DOI: 10.1111/bcp.12428

  7. You have free access to this content
    Poster Sessions


    Volume 58, Issue S1, October 2013, Pages: 92A–207A,

    Version of Record online : 1 OCT 2013, DOI: 10.1002/hep.26726

  8. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings

    Journal of Viral Hepatitis

    Volume 22, Issue 9, September 2015, Pages: 691–700, A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re III, A. C. Justice, K. E. Sherman and for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team

    Version of Record online : 18 DEC 2014, DOI: 10.1111/jvh.12375

  9. You have free access to this content
    Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 1, January 2014, Pages: 93–103, L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung and L. A. Mole

    Version of Record online : 10 NOV 2013, DOI: 10.1111/apt.12546

  10. You have free access to this content
    Drug therapy: Telaprevir


    Volume 54, Issue 4, October 2011, Pages: 1463–1469, Michael D. Leise, W. Ray Kim, Katherine M. Canterbury and John J. Poterucha

    Version of Record online : 27 SEP 2011, DOI: 10.1002/hep.24660

  11. You have free access to this content
    Effectiveness and safety of reduced-dose telaprevir-based triple therapy in chronic hepatitis C patients

    Hepatology Research

    Volume 44, Issue 10, October 2014, Pages: E163–E171, Hitomi Sezaki, Fumitaka Suzuki, Tetsuya Hosaka, Norio Akuta, Taito Fukushima, Tasuku Hara, Yusuke Kawamura, Masahiro Kobayashi, Yoshiyuki Suzuki, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda and Hiromitsu Kumada

    Version of Record online : 8 JAN 2014, DOI: 10.1111/hepr.12268

  12. You have free access to this content
    British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013

    HIV Medicine

    Volume 14, Issue S4, November 2013, Pages: 1–71, Writing Group, Dr Ed Wilkins, Dr Mark Nelson, Dr Kosh Agarwal, Ms Dola Awoyemi, Dr Eleanor Barnes, Dr Sanjay Bhagani, Dr Gary Brook, Dr Ashley Brown, Ms Sheena Castelino, Dr Graham Cooke, Prof Martin Fisher, Prof Anna Maria Geretti, Mr Robert James, Dr Ranjababu Kulasegaram, Prof Clifford Leen, Prof David Mutimer, Dr Chloe Orkin, Dr Emma Page, Dr Adrian Palfreeman, Dr Padmasayee Papineni, Dr Alison Rodger and Dr CY William Tong

    Version of Record online : 25 OCT 2013, DOI: 10.1111/hiv.12106

  13. Validation of a sensitive LC/MS/MS method for the determination of telaprevir and its R-isomer in human plasma

    Biomedical Chromatography

    Volume 28, Issue 12, December 2014, Pages: 1714–1721, Xinhui Chen, Lane R. Bushman, Kevin J. McAllister, Peter L. Anderson and Jennifer J. Kiser

    Version of Record online : 24 APR 2014, DOI: 10.1002/bmc.3211

  14. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 71–78, Véronique Loustaud-Ratti, Annick Rousseau, Paul Carrier, Chanlina Vong, Tristan Chambaraud, Jérémie Jacques, Marilyne Debette-Gratien, Denis Sautereau and Marie Essig

    Version of Record online : 27 JUL 2014, DOI: 10.1111/liv.12631

  15. You have free access to this content
    Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment


    Volume 55, Issue 4, April 2012, Pages: 1048–1057, Patrick R. Harrington, Wen Zeng and Lisa K. Naeger

    Version of Record online : 1 MAR 2012, DOI: 10.1002/hep.24791

  16. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 10, October 2011, Pages: 951–974, Olga M. Klibanov, Shannon H. Williams, Lisa S. Smith, Jacqueline L. Olin and Stephen B. Vickery

    Version of Record online : 6 JAN 2012, DOI: 10.1592/phco.31.10.951

  17. You have free access to this content
    Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 54–60, Mitchell L. Shiffman and Rafael Esteban

    Version of Record online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02718.x

  18. Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions

    Hepatology Research

    Volume 45, Issue 8, August 2015, Pages: 837–845, Goki Suda, Yoshiya Yamamoto, Astushi Nagasaka, Ken Furuya, Mineo Kudo, Yoshimichi Chuganji, Yoko Tsukuda, Seiji Tsunematsu, Fumiyuki Sato, Katsumi Terasita, Masato Nakai, Hiromasa Horimoto, Takuya Sho, Mitsuteru Natsuizaka, Kouji Ogawa, Shunsuke Ohnishi, Makoto Chuma, Yasuyuki Fujita, Riichiro Abe, Miki Taniguchi, Mina Nakagawa, Yasuhiro Asahina, Naoya Sakamoto and for the NORTE Study Group

    Version of Record online : 15 OCT 2014, DOI: 10.1111/hepr.12421

  19. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1

    Liver International

    Volume 34, Issue 6, July 2014, Pages: 869–889, Dominique Salmon-Ceron, Cédric Arvieux, Marc Bourlière, Patrice Cacoub, Philippe Halfon, Karine Lacombe, Georges-Philippe Pageaux, Gilles Pialoux, Lionel Piroth, Isabelle Poizot-Martin, Eric Rosenthal and Stanislas Pol

    Version of Record online : 25 NOV 2013, DOI: 10.1111/liv.12363

  20. You have free access to this content
    Poster Session 2: Hepatitis C: Therapeutics (Approved Agents)


    Volume 62, Issue S1, October 2015, Pages: 714A–807A,

    Version of Record online : 7 OCT 2015, DOI: 10.1002/hep.28228